Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
|Slideshows|March 26, 2021
You Spoke, We Listened. Psychiatry's Cannabis Survey
Author(s)Psychiatric Times Editors
Enlightening survey results reveal what psychiatrists think about medical marijuana/cannabis use, how or whether to discuss with their patients, and what biases might get in the way of such conversations.
Advertisement
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Check out our pipeline updates from September!
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5